Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
  • C07K14/445—Plasmodium
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
  • A61P33/06—Antimalarials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
  • C07K16/205—Plasmodium
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to novel antigens involved in gestational malaria and more particularly to polynucleotide and polypeptide sequences, conjugates, cloning vectors comprising said sequences for the production of immunogenic compositions and vaccines, antibodies and their use for the treatment of gestational malaria.
• the invention also relates to methods and diagnostic kits.
• Malaria also called malaria, is transmitted mainly by the parasite Plasmodium falciparum, inoculated during the bite of an anopheles mosquito. Once introduced into the blood, the parasite enters the liver where it matures before circulating again in the blood, infecting red blood cells (erythrocytes) and multiplying.
• Plasmodium falciparum Plasmodium falciparum
• the parasite Once introduced into the blood, the parasite enters the liver where it matures before circulating again in the blood, infecting red blood cells (erythrocytes) and multiplying.
• Gestational malaria also called placental malaria or malaria associated with pregnancy
• the placenta contains many infected erythrocytes. This has adverse effects on the growth of the fetus, since it disrupts the exchange between the mother and the fetus, resulting in a decrease in the weight of the child at birth.
• 3 to 5% of infant deaths at birth can be attributed to gestational malaria.
• gestational malaria In addition, it also presents a real danger for the mother.
• the clinical severity of malaria due to Plasmodium falciparum is partly related to alterations in infected erythrocytes.
• erythrocytes are exported to the surface of erythrocytes during the development phase in the blood.
• Some of these surface proteins, encoded by parasites confer new cytoadherence properties on erythrocytes, resulting in their subtraction from the bloodstream.
• the erythrocytes are then able to attach to the inner wall of the blood vessels, thereby preventing the transport of the erythrocyte to the purifying organs of the immune system, one of whose roles is to destroy the recognized cells. as abnormal.
• the surface proteins expressed by the parasites may also undergo antigenic variation, which is believed to contribute to the fact that the parasites escape the immune system.
• VSA surface variant antigens
• the present invention thus relates to novel polynucleotides and polypeptides involved in gestational malaria, as well as to their biological applications as sequences encoding antigens.
• Isolated or purified polynucleotides comprising a sequence selected from the group consisting of:
• SEQ ID NO. 1 corresponds to the nucleotide sequence of the hypothetical protein "PFI1785w”, described during the complete sequencing of the genome of the P. falciparum clone 3D7. However, no function has been associated with this hypothetical protein.
• sequence SEQ ID No. 2 thus corresponds to the peptide sequence of the hypothetical protein "PFI1785w".
• the invention relates more particularly to polynucleotides having a sequence chosen from the group consisting of:
• SEQ ID NO. 3 corresponds to the nucleotide sequence fragment studied by the inventors and used when carrying out a particular embodiment of the invention (see FIG. Example 1). This sequence encodes a protein designated "NP561" by the inventors.
• the invention also relates to the polypeptides corresponding to the abovementioned polynucleotides and more particularly to the isolated or purified polypeptides encoded by the above polynucleotides, as well as the isolated or purified polypeptides comprising a sequence chosen from the group consisting of:
• the invention also covers recombinant or chimeric polypeptides comprising at least one polypeptide according to the invention.
• polypeptides and polynucleotides according to the invention are particularly suitable for use as medicaments.
• the polypeptides according to the invention constitute antigens of gestational malaria.
• polynucleotides encode antigenic proteins of this specific malaria. As such, they can be used as such or in modified form as vaccines.
• An appropriate modification of the polypeptides according to the invention corresponds to the production of conjugates. These comprise at least one polypeptide according to the invention, bound to a support.
• the conjugates can be obtained by coupling via a covalent bond between a polypeptide and a physiologically acceptable, non-toxic, natural or synthetic carrier, capable, for example, of increasing the immunogenic nature of said polypeptide.
• a physiologically acceptable, non-toxic, natural or synthetic carrier capable, for example, of increasing the immunogenic nature of said polypeptide.
• the preferred supports according to the invention are chosen from viral particles, lipids, for example lipids of the C16-C18 type, polylysines, poly (DL-alanine) -poly (-Lysine) s, nitrocellulose and microparticles. of polystyrene, latex ball microparticles, biodegradable polymers, polyphosphoglycan microparticles, carrier proteins such as OPMC
• OPMC outer membrane protein complex of Neisseria meningitidis
• BSA bovine serum albumin
• TT tetanus toxoid
• ovalbumin KLH (keyhole limpet hemocyanm)
• THY bovine thyroglobulin
• l Hepatitis B virus HBsAg and HBcAg rotavirus capsid proteins
• human papillomavirus LI protein virus type particle 6, 11 and 16, tuberculin PPD (purified protein de ⁇ vative) ...
• the invention also provides a cloning or expression vector comprising at least one polynucleotide sequence according to the invention.
• the vectors targeted by the invention may be phages, plasmids, cosmids, viruses.
• the vector according to the invention may advantageously comprise a promoter and / or an element for regulating the expression in the host cell.
• the vectors may comprise sequences capable of increasing the immunogecity of the polynucleotides and polypeptides according to the invention, for example CpG sequences, the GMCSF gene (Granulocyte Macrophage Colony Stimulating Factor) or genes of cytokines or chemokines.
• Transformed (or recombinant) host cells comprising at least one polynucleotide or vector according to the invention are also within the scope of the invention.
• These cells may be chosen from bacteria, yeasts, insect or mammalian cells.
• conjugates and cloning vectors according to the invention may advantageously be used as medicaments, especially in immunogenic compositions or vaccines.
• the cloning vector can be used as a drug in the context of a DNA vaccination. It is indeed known that the injection of DNA (naked or inserted into a vector) in the body can allow the expression of the corresponding proteins and lead to an immune response.
• the polynucleotides according to the invention may advantageously be inserted into a plasmid of the DNA-CSP type, Nyvac pf7, VR1020, VR1012 ...
• the invention proposes immunogenic, pharmaceutical or gestational malaria vaccines comprising at least one element selected from polynucleotides, polypeptides, conjugates or vectors according to the invention, in association with an acceptable pharmaceutical carrier.
• the immunogenic compositions and vaccines can be advantageously used to immunize animals for the purpose of obtaining antibodies, or to immunize humans as part of a preventive treatment of gestational malaria.
• the composition or the vaccine may be adjuvanted by one or more adjuvants used in combination.
• adjuvants such as Montanide and / or Alum may be used.
• other adjuvants such as QS21, SBAS2, MF59, mLT, PHL, CpG DNA, calcium phosphate, dehydrated calcium sulfate, PLG, CT, LTB, CT / LT, AS02A are also suitable.
• the immunogenic compositions and vaccines according to the invention may also comprise at least one specific antigen of P.
• falciparum selected from var2csa pre-erythrocyte stage antigens (CSP, TRAP, LSA-I, LSA-3, SALSA, STARP, EXP - 1), asexual erythrocytes (MSP-I, MSP-3, AMA-I, EBA-175, GLURP, MSP-2, MSP-4, MSP-5, RAP-2, RESA, sera, PfEMP-I, toxin Synthetic GPI) or sexed (PfS25).
• CSP pre-erythrocyte stage antigens
• TRAP pre-erythrocyte stage antigens
• LSA-I LSA-I
• LSA-3 LSA-3
• SALSA SALSA
• STARP STARP
• EXP - 1 asexual erythrocytes
• the immunogenic composition or vaccine may be formulated for intradermal or intramuscular administration.
• an advantageous dosage is from 1 to 100 ⁇ g of immunogen per injection, preferably 5 to 50 ⁇ g.
• the invention also provides monoclonal, polyclonal or anti-sera antibodies specifically recognizing at least one of the polypeptides and / or conjugates according to the invention.
• these antibodies will be recombinant, humanized or chimerized antibodies, in particular when they will be used as medicaments, in the context, for example, of passive immunotherapy of gestational malaria.
• the invention particularly covers the use of at least one element selected from polynucleotides, polypeptides, conjugates, vectors, antibodies according to the invention, for the manufacture of a medicament for the treatment of placental malaria. It also provides in vitro diagnostic methods for placental malaria in a woman who may be infected with P. falciparum.
• a first method it comprises the following steps: a) bringing into contact, under conditions allowing an immunological reaction, a tissue and / or a biological fluid taken from the woman likely to be infected, with an antibody according to the invention, to allow the formation of immune complexes; and, b) detecting said potentially formed immune complexes.
• a diagnostic kit that can advantageously be used in the context of the method above, is also proposed. It includes the following elements:
• reagents allowing the detection of antigen-antibody complexes produced by said binding, these reagents being able to carry a marker capable of being recognized by a second detection reagent.
• the diagnostic method comprises the following steps: a) bringing into contact, under conditions allowing an immunological reaction, a tissue and / or a biological fluid taken from the woman likely to be infected with at least one member selected from the polypeptides, the conjugates according to the invention, to allow the formation of immune complexes with the antibodies possibly present in said tissue and / or said biological fluid; and, b) detecting said potentially formed immune complexes.
• the invention also covers the polynucleotide and polypeptide sequences of the proteins
• Figure 1 relates to the transcription characteristics of placental isolates.
• the points indicate the Iog2 of the log ratio of the expression (M) and the mean intensity (A) for each group of isolates in comparison with the control (strain 3D7). Only statistically significant data according to the Bonferroni correction are indicated.
• a single dominant var gene (var2csa) was detected in placental isolates of all examined groups (red dots). Over-expressed or under-regulated genes are indicated in black when the same difference is present in the three groups, in green when it is present in 2 groups out of 3 (2/3) and in blue when this one is present in 1 in 3 groups (1/3).
• Figure 2 shows the transcription levels of the genes identified in P. falciparum.
• PW primary publical malaria
• C asymptomatic children
• NPW Non-pregnant symptomatic women
• FIG. 2 shows the transcription levels of the genes identified in P. falciparum.
• PW primary publical malaria
• C asymptomatic children
• NPW Non-pregnant symptomatic women
• 3D7 black diamonds
• FCR3 red triangles
• Hb3 yellow diamonds
• NF54 green squares.
• Each of these 4 strains was used after selection or non-selection by the CSA link using soluble CSA (3D7), BeWo cells (FCR3 and Hb3) or anti-VAR2CSA IgGs (NF54).
• Figure 3 illustrates the ELISA recognition of NP561 by sera from individuals exposed to malaria.
• the test ELISA was conducted on plates covered by the NP561, DBL5- ⁇ , VAR2CSA and GLURP protectors.
• the high, low and mid sticks lines correspond to the 75 th percentile, 25 th percentile and 50 th percentile (median), respectively.
• the upper and lower marks extend to the 90 th and the io th percentile.
• Plasma concentrations of anti-VAR2CSA and anti-NP561 IgG were significantly higher in pregnant women.
• Figure 4 depicts the immunoblot-detected reactivity of rabbit anti-NP561 IgG against SDS lysates of P. falciparum-infected erythrocytes (PI: placental isolate, Ch: child isolate).
• the arrows indicate the expected size of the protein corresponding to PFI1785w.
• Figure 5 shows a flow cytometry and confocal microscopy analysis of erythrocytes labeled with anti-NP561 IgG or with irrelevant control antibody.
• A Labeling of uninfected red blood cells with anti-NP561 IgG and control of PBS-FCS on placental parasites.
• B
• Figures 6A and 6B show the splice structure of PFI1785w.
• Figure 7 the alignments respectively, sequences determined from the gDNA strain 3D7; gDNA of placental isolates; the cDNA of strain 3D7; the cDNA of the Senegalese placental isolate N42; the cDNA of the Senegalese placental isolate N14; the sequence predicted in plasmo DB from the cDNA of strain 3D7; and the consensus sequence.
• Example 1 Identification of New Genes with Specificity for Placental Tropism
• the red blood cells of the peripheral blood were washed 3 times and incubated in RPMI medium at 37 ° C in a candle bell (microaerophilic atmosphere) for 18-2Oh allowing the maturation of the ring stages in trophozoites.
• RPMI medium 37 ° C in a candle bell (microaerophilic atmosphere) for 18-2Oh allowing the maturation of the ring stages in trophozoites.
• a thick blood smear was prepared for microscopic examination from placenta appositions.
• P. falciparum-infected erythrocytes were isolated from positive placentas by infusion of said placentas with 0.1% heparin sodium in PBS (phosphate buffer saline).
• PBS phosphate buffer saline
• venous blood samples were collected from non-symptomatic infected children in a parallel cross-sectional study in the Thiebenegal. The samples were collected according to the same protocols described above.
• Bovine CSA (Sigma) and human chondroitin sulfate proteoglycans (CSPGs) were deposited as circular tasks in Falcon Petri dishes (Becton Dickmson) and the level of adherence to CSA and CSPG of Placental parasites were quantified according to the number of infected erythrocytes observed per square millimeter, estimated by examination of 20 fields under a high magnification microscope (20 times).
• Strains of P. falciparum were grown according to previously described protocols (Trager and Jensen, 1976).
• the strain 3D7 was synchronized with sorbitol 4 times with an interval of 8 hours in order to obtain particularly well synchronized development stages.
• Strains FCR3 and HB3 were selected according to their adhesion to CD36 or Bewo cells.
• the strain NF54 was selected using antibodies specific for the PfEMP1 protein encoded by the var2csa gene.
• the strain 3D7 was also selected according to its adhesion to the immobilized CSA. After selection, the parasites were cultured for 5-6 cycles to generate sufficient parasite density. The enrichment in mature cells is carried out by Macs purification as previously described (Staalsoe et al.
• the parasites are allowed to re-contaminate new red blood cells and are then recovered at 18, 36 and 44 hours after the invasion. Gender-specific recognition of the selected parasites was measured by flow cytometry using plasma samples from pregnant women and adult men from endemic areas, as well as samples of non-immune Danish volunteers (control).
• Genomic DNA was extracted from Whatman's paper deposits using the Chelex procedure
• RNA from placenta-infected erythrocytes and mature peripheral blood containing trophozoite / schizont stage parasites was prepared with Trizol. The quality of the RNA has been verified with the Agilent 2100 Bioanalyzer.
• Genotyping msp-2 The parasites were genotyped by analysis of the central msp-2 domain.
• the PCR amplification was carried out as previously described (Jafary et al., 2004) using primers fw (SEQ ID No. 15): 5'-GAAGGTAATTAAAACATTGTC-3 '(5' being fluorescein labeled) and rv (SEQ ID No. 16): 5'-GACACCTCGTCGTTGTAGGGAG-3 '.
• the amplification products are passed to the ABI Prism 310 Genetic Analyzer (Perkin Elmer Applied Biosystems) to enumerate and quantify the fluorescent fragments.
• RNA samples from 18 women were assembled into three groups and the control (3D7) consisted of a mixture of different stages of parasite development was prepared (Table 1). The integrity of the RNA transcripts of each sample was verified with the Agilent 2100 Bioanalyzer. The labeling and hybridization of the RNA samples were performed according to previously described protocols (Ralph et al., 2005).
• RNA extraction in t ⁇ zol is followed by a 15 min treatment with DNase 1 (Sigma) at 37 ° C.
• DNase 1 Sigma
• the absence of DNA contaminant in the preparation was verified using 40 cycles of real-time PCR using primers specific for a conserved housekeeping gene (f ructose-biphosphate aldolase).
• DNA-free RNA has was transcribed by reverse transcription using random primers with the enzyme Superscript II (Invitrogen) at 25 ° C for 10 min, then at 42 ° C for 50 min followed by a cycle at 70 0 C for 15 min.
• the PlasmoDB predicted protein encoded by the PFI1785w gene of the P. falciparum clone 3D7 genome was selected to be expressed as a soluble protein.
• the product of this gene is a protein of 332 amino acids with a transmembrane domain extending from amino acid 41 to amino acid 69 and a pexel motif located between amino acids 86 and 92.
• the sequence from base pair 391 to base pair 967 is amplified from 3D7 gDNA using the following primers, which include EcoRI and NotI restriction sites at 5 'and 3' respectively: Fw ( SEQ ID No.
• NP561 corresponding to approximately 70% of the complete size of the PFI1785w protein, was used as an immunogen in this study.
• Specific rabbit antibodies were induced as described previously (Salanti et al., 2004) and affinity purified using a column where the recombinant NP561 was fixed. Briefly, NP561 was covalently coupled via primary amino groups to a HiTrap TM NHS-activated Sepharose column and the rabbit antibodies were purified according to the manufacturer's instructions.
• Plasma levels of P. falciparum specific IgG were measured by ELISA using recombinant proteins VAR2CSA and NP561 as antigens.
• the recombinant GLURP protein was used as a control antigen.
• Antibody levels are expressed as optical density (OD) values. Characterization of antibodies by immunodetection by electrophoretic transfer (Iinmunoblot).
• the polyclonal antibodies against NP561 are affinity purified from hyperimmune rabbit sera and a group of plasma samples from women suffering from of placental infection and their reactivity was tested on the surface of mature infected erythrocytes from childhood isolates and placental isolates from Africa. The reactivity of the antibodies with the surface of infected erythrocytes in the liquid phase was then verified by confocal microscopy, using an LSM5 microscope (Carl Zeiss Microlmagming, Inc.).
• RNAs from different stages of development of strain 3D7 have been grouped together to mimic the distribution stages in placental isolates.
• the RNA sample pools were fluorescently labeled and hybridized with a high density oligonucleotide array (Ralph et al., 2005).
• a reversal of the markers is performed. Bonferroni's method, the most recent one, showed that 183 genes were overexposed in placental parasites and 261 genes were under-expelled.
• 99 belong to group 1, 67 to group 2 and 85 to group 3. The majority of these genes (108 out of 183) correspond to hypothetical proteins. 20 of them have a pexel pattern.
• RNAs corresponding to the 19 genes differentially expressed with level variations as estimated by the oligonucleotide network were carried out.
• the genes were chosen from the abundance of their transcripts, which varies from strong to weak. Additional criteria include: 1) be overexposed steadily to 2 of the 3 groups, n) have at least one TM, pexel and / or signal sequence, m) be also present in another biochip analysis using laboratory isolates selected for their specific phenotype.
• the abundance of transcripts from the 19 selected genes was determined by real - time PCR in parasites associated with different clinical presentations of malaria infection. Parasites were collected from asymptomatic children and non-pregnant women with symptoms, living in a geographical area close to western Senegal on a short time interval compared to placental samples. The abundance of transcripts corresponding to the 19 genes was measured on parasites having reached a degree of maturation and development approximately identical to those of parasites derived from placentas. The abundance of transcripts of the 19 genes was also measured on laboratory-adapted parasite lines selected for their phenotype capable of binding to the CSA or not.
• var2csa has a specific PAM profile in the isolates as well as a marked specificity for the laboratory isolates selected for their binding to the CSA (Salanti et al., 2003), (Fig. 2, right panel).
• Fig. 2B m) high expression in parasites from women with symptoms and pregnant women but no asymptomatic children (shown in Fig. 2C), iv) no difference in expression among all groups of parasites in vivo (not shown)
• the protein has a surface expression with a short N-terminal domain.
• PF10_0350 which is highly transcribed in non-PAM parasites with respect to placental parasites.
• the product of this gene is predicted to have surface expression, since it has a transmembrane domain, but no pexel motif targeting red cell surface targeting.
• PfEMP1 variants as the major mediator of the antigenic variation and adhesion properties of infected erythrocytes.
• Tuikue Ndam et al., 2005 demonstrated that VAR2CSA PfEMPl is responsible for the binding to CSA of infected erythrocytes from the placenta.
• the present study has identified differences in gene expression compared to the parasites in the 3D7 laboratory control strain, using a biochip analysis of the entire genome of the parasites. Placental P. falciparum.
• placental parasites which along with var2csa, includes genes considered likely to encode surface proteins that may play a role in the biological process associated with placental tropism. parasites.
• var2csa genes considered likely to encode surface proteins that may play a role in the biological process associated with placental tropism. parasites.
• RNA expression were minimized by (1) sampling of patients of the same ethnic group, living in the same geographic area and having the same type of disease (placental infection), (2) grouping of samples according to a distribution relative to the stage of development of the parasite, the analysis of homogeneous parasites being richer in information with regard to commonly shared properties.
• NP561 Part of the protein encoded by PFI1785w was expressed in recombinant baculovirus-infected sf9 insect cells with the PFI1785w gene sequence, and the product (NP561) was purified as a protein with a secreted histidine tail. NP561 has been recognized in tests
• IFA infected erythrocytes derived from placenta.
• PfEMP rabbit antisera directed against other previously characterized PfEMPs against uninfected erythrocytes, erythrocytes infected with laboratory strains and infected fresh erythrocytes from children.
• recombinant NP561 specific rabbit antibodies were able to specifically mark the surface of parasitized red blood cells derived from placenta but not that of red blood cells infected with strains of laboratory parasites or that of infected erythrocytes from children (Fig. 5).
• the surface location of the protein corresponding to PFI1785w is clearly demonstrated by confocal microscopy after IFA.
• the protein is specifically located on the surface of infected erythrocytes derived from placenta.
• PFI1785w has a clearly defined profile, similar to that of var2csa, suggesting its specificity to PAM.
• no evidence of a possible relationship to a CSA binding phenotype was observed in biologically-selected in vitro parasite lines for binding to CSA.
• CSA binding properties represent a major specific phenotype of MAP parasites, it appears that all parasite characteristics PAM managers can not be reproduced in laboratory-adapted parasite lines.
• Further work to characterize PFI1785w revealed that the protein encoded by this gene is expressed by placental isolates as demonstrated by western blot analyzes.
• NP561 Compared to VAR2CSA, the corresponding recombinant protein (NP561) is better recognized by serum samples from pregnant women living in endemic areas of malaria suggesting that the product of this gene is targeted by the immune response, although its relationship to genus less important.
• specific antibodies directed against NP561 specifically mark the surface of PAM parasites as demonstrated by flow cytometry and IFA. This proves an obvious implication of this parasitic protein in PAM mechanism.
• PFI1785w is a gene with a unique copy that encodes a small protein that is predicted to express a single molecule on the surface of erythrocytes. This new immunoreactive antigen identified has interesting evidence of its involvement in the mechanism governing placental tropism of P. falciparum, and thus appears as a new priority antigen for evaluations aimed at developing an effective vaccine against MAP. .
• Figure 7 gives comparisons between genomic or cDNA sequences of a Plasmodium strain or placental isolates.
• the predicted sequence of PlasmoB which is obtained from the 3D7 cDNA, comprises a "stop" bead.
• the region Corresponding text is not translated. This sequence is therefore truncated, the bases 555 to 647 being missing.
• This sequence can be translated from gDNA (3D7 DNA and gDNA from a Ghana isolate).
• the cDNAs of isolates N42 and N14 have no mtrons.
• PF10_0350 and PF10_0351 are contiguous and in the same orientation on chromosome 10. It is interesting to note that one is over-regulated while the other is under-regulated in placental samples. Since there is only 1.3 kb between the "stop" codon of PF10_0350 and the "start” codon of PF10_0351, it can be assumed that the attachment of the activating zone on the promoter region of PF10 0351 interferes with the enhancer. the 5 'region of PF10 0350.
• PF10_0351 belongs to the family of paralogs of MSP3 (merozoite surface protein 3). H103, the protein encoded by PF10_0351, has been shown to be expressed on the surface of merozoites (Pearce et al., 2005). Overexpression of this protein in placental parasites may indicate that H103 acts as a virulence factor. In the present study, the differences between the in vivo parasites and the in vitro parasite cultures are clearly evidenced by the transcription of genes such as PFCOI10w (Clag 3.2), PF10_0344 (glutamate-rich protein) and PF14_0010 (antigen relative to the glycophenic binding protein). PFC0120w that codes for a different member of the CLAG family
• clag 3.1 (asexual cytoadherence gene), clag 3.1, is, however, underregulated in placental parasites, probably indicating that the latter is not involved in the in vivo pathogenesis of PAM parasites.
• subfamily clag genes (dag3) have been described as playing a possible role in erythrocyte binding during the invasion process, recent studies show that clag 3.2 transcripts, unlike those of clag 3.1, can not be detected in some laboratory-adapted strains, such as Dd2 parasites, which is consistent with this study.
• ⁇ D shows the PCR products confirming the splicing of intron 1 and not intron 2 in 3D7 and a placental isolate cDNA.
• the 3 primers represented by arrows in Fig. B were used to amplify a short fragment and a complete fragment from the 3D7 genomic DNA (lines 2 and 5), the 3D7 cDNA (lines
• Line 1 shows a molecular weight marker of
• ⁇ D (B) represents the pattern of the exon / mtron structure from the predicted gene and mRNA / cDNA.
• the black bars represent the predicted exons.
• the white and striped bars represent intron 1 and intron 2, respectively, according to the genome sequence of 3D7.
• the mRNA / cDNA pattern corresponds to the structure observed experimentally.
• Rabbit antibodies specific for these recombinant proteins were able to specifically mark the surface of parasitized red blood cells derived from placenta but not that of red blood cells infected with strains of laboratory parasites or that of infected erythrocytes from children.
• the surface localization of the proteins corresponding to PFA0700c, PF14_0757, PFB0105c, PF10_0351 and PF10_0350 was verified by confocal microscopy after IFA.
• Antibodies specific for each of the above proteins were used in immunoprecipitation on parasitized and desequered red blood cell lysates of placentas. Protein complexes were dissociated and analyzed by mass spectrometry. The combination of all these methods allowed us to confirm the expression, the export to the surface of the parasitized red blood cell and the antigenicity of new parasite proteins involved in the pathogenesis of gestational malaria. These proteins are therapeutic and vaccine targets of great interest.
• Rabbits are immunized with incomplete / complete Freund's adjuvant. This adjuvant helps to induce the production of reactive antibodies directed against NP561.
• the levels of NP561 specific IgGs are detected by ELISA and increase as immunizations proceed and reach a maximum after 5 immunizations (Barfod et al., 2006).
• the polyclonal antibodies against NP561 are affinity purified from sera of human rabbits. References
• Plasmodium falciparum dihydrofolate reductase polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52: 565-568.
• VAR2CSA Plasmodium falciparum-infected erythrocytes.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Tropical Medicine & Parasitology (AREA)
• Immunology (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Toxicology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=38613117

Family Applications (1)

Country Status (5)

Families Citing this family (2)

Family Cites Families (2)

• 2007
  • 2007-04-17 FR FR0702772A patent/FR2915207B1/fr not_active Expired - Fee Related
• 2008
  • 2008-04-17 EP EP08737901A patent/EP2145003A2/de not_active Withdrawn
  • 2008-04-17 AP AP2009005041A patent/AP3116A/xx active
  • 2008-04-17 US US12/450,874 patent/US8563008B2/en not_active Expired - Fee Related
  • 2008-04-17 WO PCT/IB2008/051482 patent/WO2008126065A2/fr active Application Filing

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events